Global Small Molecule API Market Size study, by Type (Synthetic, Biotech), By Application (Oncology, Pulmonology, CNS, Endocrinology, Cardiology, Orthopedic, Endocrinology, Gastroenterology, Nephrology, Ophthalmology, Others), By Manufacturer (In-house, O

Global Small Molecule API Market Size study, by Type (Synthetic, Biotech), By Application (Oncology, Pulmonology, CNS, Endocrinology, Cardiology, Orthopedic, Endocrinology, Gastroenterology, Nephrology, Ophthalmology, Others), By Manufacturer (In-house, Outsourced) and Regional Forecasts 2022-2028

Global Small Molecule API Market is valued at approximately USD 175 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 5.4% over the forecast period 2022-2028. A small active pharmaceutical ingredient (API) molecule is a low-molecular-weight organic component. It is a pharmaceutically active ingredient that is used in biological procedures. Furthermore, API can be combined in finished pharmaceutical products. As a critical component, its demand in the pharmaceutical industry is high. The molecule is useful in the diagnosis, treatment, and prevention of a wide range of diseases. Small API molecules can be used as research tools to investigate biological function and to help develop new therapeutic agents. Some can obstruct a protein's specific function or disrupt protein-protein interactions. The growing demand for small molecule drugs in the market, as well as the increased outsourcing trend, are two major factors driving the market. The patent expiration of leading molecules is further driving growth by allowing new players to enter the market, which drives demand for raw materials such as API for low-cost drug production. For example, Sumitomo Chemical Co., Ltd. announced in March 2022 that it would invest in a new manufacturing facility in Japan to meet the surge in demand for high-quality small molecule APIs and intermediates. Because a large number of companies manufacture their API in-house, they are less reliant on raw material suppliers. For example, AstraZeneca announced a USD 360 million investment in an API manufacturing facility in Ireland for the commercialization of new products in September 2021. Furthermore, rising technological developments in the manufacturing sector are propelling the global small molecule API market forward. However, the government's stringent regulations on the use of small molecules limit the market growth.

The key regions considered for the global Small Molecule API market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America held the largest market share. The presence of favourable government initiatives, combined with increased interest from regional players, are expected to propel the North American market. Whereas, due to improvements in overall healthcare infrastructure, improved access to healthcare, and the presence of a large number of local manufacturers, Asia Pacific is expected to be the fastest-growing region during the forecast period. These players supply globally, making Asia Pacific a key region for low-cost small molecule API production.

Major market players included in this report are:
Merck & Co., Inc.
AbbVie, Inc.
Bristol-Myers Squibb Company
Albemarle Corporation
Boehringer Ingelheim International GmbH
Cipla, Inc.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
Dr. Reddy’s Laboratories Ltd.
Aurobindo Pharma
Sun Pharmaceutical Industries Ltd.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Synthetic
Biotech
By Manufacturer:
In-house
Outsourced

By Application:
Cardiology
Oncology
CNS and Neurology
Orthopedic
Endocrinology
Pulmonology
Gastroenterology
Nephrology
Ophthalmology
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Small Molecule API Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Merck & Co., Inc.
AbbVie, Inc.
Bristol-Myers Squibb Company
Albemarle Corporation
Boehringer Ingelheim International GmbH
Cipla, Inc.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
Dr. Reddy’s Laboratories Ltd.
Aurobindo Pharma
Sun Pharmaceutical Industries Ltd.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.